Virtual reality simulation training in a high-fidelity procedure suite: operator appraisal.

Purpose: To assess the face and content validity of a novel, full physics, full procedural, virtual reality simulation housed in a hybrid procedure suite.

Methods And Materials: After completing 60 minutes of hands-on training in uterine artery embolization and coronary angioplasty, 24 radiologists and 18 cardiologists with mean 10 years of endovascular experience assessed the functionality of a comprehensive hybrid procedure suite simulation (Orcamp; Orzone, Gothenburg, Sweden).

Results: C-arm and operating table functionality and realism were reliably (α = 0.

Plasma B-type natriuretic peptide levels in cardiac donors.

Introduction: Elevated levels of plasma brain natriuretic peptide (BNP) and amino-terminal BNP (NT-proBNP) are associated with adverse cardiac outcomes. It is not known whether BNP and NT-proBNP levels in heart donors can aid in selection and predict outcomes in transplant recipients.

Methods: Plasma BNP and NT-proBNP were measured in 32 organ donors prior to removal from life-support systems.

Frequency of recurrent ST-elevation myocardial infarction after fibrinolytic therapy in a different territory as a manifestation of multiple unstable coronary arterial plaques.

Multiple unstable plaques have been demonstrated by various imaging techniques in culprit and nonculprit arteries in patients with acute coronary syndromes, but the frequency with which clinical manifestations of multiple unstable plaques occur is unclear. To estimate this frequency in patients who present within 6 hours with ST-elevation myocardial infarction, we studied electrocardiograms and cardiac marker levels of 722 patients with suspected reinfarction in the HERO-2 trial of 17,073 patients; this trial compared intravenous bivalirudin with unfractionated heparin before administration of streptokinase. Twenty-six patients (3.

Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction.

The direct thrombin inhibitors hirudin and bivalirudin inhibit both fluid-phase and clot-bound thrombin. These agents have been extensively studied in clinical trials in comparison with intravenous unfractionated heparin (UFH), as adjuncts to fibrinolytic therapy for ST-elevation myocardial infarction (STEMI) and in percutaneous coronary intervention (PCI), and they are currently undergoing further evaluation in patients with non-ST elevation acute coronary syndromes (NSTEACS). In angiographic trials there were trends for patients treated with hirudin to be more likely to achieve Thrombolysis In Myocardial Infarction (TIMI) grade 3 flow at 90 minutes than patients treated with UFH (65% versus 57% in TIMI-5; 41% versus 33% in Hirudin for the Improvement of Thrombolysis [HIT]-4; statistically nonsignificant differences in both trials).

Prospective evaluation of a chest pain pathway at Green Lane Hospital.

Aims: To prospectively evaluate the efficacy and safety of a chest pain pathway at Green Lane Hospital.

Methods: Between August 1999 and March 2000, patients with non-traumatic chest discomfort considered to be possibly ischaemic were assessed by history, physical examination, baseline electrocardiographic findings and point of care troponin T tests. Those considered not to be high risk entered the pathway which included repeat cardiac markers and electrocardiograms at 6-8 hours, followed by optional stress testing.

Stent deployment with distal vascular protection for the culprit vein graft stenosis in a patient with an acute infarct and cardiogenic shock.

A case of emergency stent deployment to a critical vein graft lesion in a patient with an acute myocardial infarction and cardiogenic shock is described. An Angioguard vascular protection device was used, retrieving a large amount of atheromatous debris. Use of filter-type protection devices to prevent distal atheroembolism may be lifesaving in such patients.